Questionable long-term benefit of initial temozolomide monotherapy in IDH-mutant astrocytomas grade 2 and 3

Authors :: Weller, J
Katzendobler, S
Quach, S
Becker, H
Thiele, F
Dorostkar, M
Suchorska, B
Thon, N
Tonn, JC
Source :: 73. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC), Joint Meeting mit der Griechischen Gesellschaft für Neurochirurgie; 20220529-20220601; Köln; DOCV132 /20220525/
Publication Year :: 2022
Publisher :: German Medical Science GMS Publishing House, 2022.
Abstract: Objective: The role of temozolomide monotherapy in IDH-mutant (IDHmut) astrocytomas after biopsy or tumor resection has not been conclusively determined. Methods: In this retrospective, single-center study, 151 patients with IDHmut WHO grade 2 or 3 according to WHO 2016 and seen between 2001 [for full text, please go to the a.m. URL]

Language :: English
Database :: OpenAIRE
Journal :: 73. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC), Joint Meeting mit der Griechischen Gesellschaft für Neurochirurgie; 20220529-20220601; Köln; DOCV132 /20220525/
Accession number :: edsair.doi.dedup.....8c2b85d377edc0d8fb00e9e722adb3c6
Full Text :: https://doi.org/10.3205/22dgnc132

Full Text Access

Tools